An Experimental Ebola Vaccine.
Early results suggest an exploratory Ebola vaccine triggers an untouched response and is safe to use. However, larger clinical trials in West Africa are needed to affect if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the UK This vaccine innards against the Zaire damage of Ebola currently circulating in West Africa. It doesn't contain contagious Ebola virus material, so it cannot cause Ebola infection in people who receive it.
The vaccine is being developed by the US National Institutes of Health and GlaxoSmithKline. The beforehand doses of the vaccine for use in staggering clinical trials in West Africa have been delivered to Liberia. The Oxford University whirl included 60 healthy volunteers who were monitored for 28 days after receiving three unheard-of doses of the vaccine. The volunteers will continue to be monitored for six months. "The vaccine was well tolerated.
Showing posts with label oxford. Show all posts
Showing posts with label oxford. Show all posts
Saturday 8 June 2019
Thursday 7 March 2019
New Blood Test Can Detect Prostate Cancer More Accurately And Earlier
New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A untrodden blood probe to spot a cluster of specific proteins may evidence the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a lead study, is 90 percent accurate and returned fewer false-positive results than the prostate fixed antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British public limited company that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.
The examine looks for auto-antibodies for cancer, alike to the auto-antibodies associated with autoimmune diseases such as variety 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's transgression president of biomarker discovery. "We're tiring to look for antibodies generated in the beginning stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".
Such a study generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a unassuming blood test". The researchers came up with groups of up to 15 biomarkers that were exhibit in prostate cancer samples and not present in men without prostate cancer. The exam also was able to differentiate actual prostate cancer from a more benign condition.
Because a apparent is currently pending, Anson would not list the proteins included in the test. "We are prosperous on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a well range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".
A untrodden blood probe to spot a cluster of specific proteins may evidence the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a lead study, is 90 percent accurate and returned fewer false-positive results than the prostate fixed antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British public limited company that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.
The examine looks for auto-antibodies for cancer, alike to the auto-antibodies associated with autoimmune diseases such as variety 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's transgression president of biomarker discovery. "We're tiring to look for antibodies generated in the beginning stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".
Such a study generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a unassuming blood test". The researchers came up with groups of up to 15 biomarkers that were exhibit in prostate cancer samples and not present in men without prostate cancer. The exam also was able to differentiate actual prostate cancer from a more benign condition.
Because a apparent is currently pending, Anson would not list the proteins included in the test. "We are prosperous on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a well range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".
Subscribe to:
Posts (Atom)